Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 9/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 9/20 | 0.37 |
| ▸ | LAP3 | P28838 | 4/20 | 0.36 |
| ▸ | ANPEP | P15144 | 3/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28457390 | 0.80 | BIRC2 (0.37) | TAS1R3TAS1R1 | |
| SCHEMBL28457393 | 0.80 | BIRC2 (0.37) | TAS1R3TAS1R1 | |
| SCHEMBL5050593 | 0.79 | CA12 (0.33) | MMP1MMP9 | |
| SCHEMBL28455795 | 0.79 | CA12 (0.33) | MMP1MMP9 | |
| SCHEMBL28450360 | 0.78 | L3MBTL1 (0.39) | TAS1R3TAS1R1ALDH1A1 | |
| SCHEMBL28449915 | 0.77 | CTSK (0.46) | — | |
| SCHEMBL10004949 | 0.76 | CA12 (0.35) | MMP1MMP9 | |
| SCHEMBL1810431 | 0.75 | ANPEP (0.45) | TAS1R3TAS1R1LAP3ANPEPMMP1 | |
| SCHEMBL14240482 | 0.74 | ALDH1A1 (0.39) | TAS1R3TAS1R1ANPEPALDH1A1NOS3 | |
| SCHEMBL30057219 | 0.72 | ALDH1A1 (0.55) | LAP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031745-A1 | Antiviral purine derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031745-A1 | Antiviral purine derivatives | PNP, TYMP, MTAP | TAS1R3 4389/4885TAS1R1 3762/4885LAP3 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.